Your browser is no longer supported. Please, upgrade your browser.
BCRX BioCryst Pharmaceuticals, Inc. monthly Stock Chart
BCRX [NASD]
BioCryst Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.76 Insider Own0.10% Shs Outstand176.52M Perf Week1.75%
Market Cap792.43M Forward P/E- EPS next Y-0.86 Insider Trans46.53% Shs Float175.07M Perf Month21.35%
Income-124.90M PEG- EPS next Q-0.21 Inst Own73.30% Short Float23.60% Perf Quarter16.94%
Sales53.50M P/S14.81 EPS this Y4.00% Inst Trans-4.66% Short Ratio8.26 Perf Half Y3.67%
Book/sh0.19 P/B24.53 EPS next Y10.40% ROA-71.10% Target Price- Perf Year79.92%
Cash/sh0.84 P/C5.53 EPS next 5Y19.90% ROE-328.70% 52W Range1.58 - 6.29 Perf YTD35.07%
Dividend- P/FCF- EPS past 5Y-6.80% ROI-84.10% 52W High-25.87% Beta2.77
Dividend %- Quick Ratio1.40 Sales past 5Y29.10% Gross Margin92.20% 52W Low194.94% ATR0.27
Employees140 Current Ratio1.50 Sales Q/Q238.90% Oper. Margin- RSI (14)64.18 Volatility6.79% 6.44%
OptionableYes Debt/Eq2.26 EPS Q/Q23.30% Profit Margin- Rel Volume1.54 Prev Close4.40
ShortableYes LT Debt/Eq0.80 EarningsNov 05 BMO Payout- Avg Volume5.00M Price4.66
Recom2.10 SMA2013.16% SMA5019.87% SMA20021.98% Volume7,626,096 Change5.91%
Sep-29-20Resumed JP Morgan Overweight $7
Jun-17-20Initiated BTIG Research Neutral
May-05-20Upgrade Barclays Equal Weight → Overweight $7
Nov-15-19Upgrade BofA/Merrill Neutral → Buy $5 → $4
May-24-19Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4.50
Nov-16-18Resumed Piper Jaffray Overweight $15
Aug-08-18Resumed JP Morgan Overweight $9
Jul-17-18Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18Initiated Seaport Global Securities Neutral
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-20-17Initiated Barclays Equal Weight $6
Sep-15-17Initiated RBC Capital Mkts Sector Perform $6
Sep-06-17Upgrade JP Morgan Neutral → Overweight
Sep-06-17Upgrade Jefferies Hold → Buy
Feb-16-17Initiated Ladenburg Thalmann Buy $11
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated FBR Capital Outperform $18 → $6
Feb-09-16Downgrade Needham Buy → Hold
Feb-09-16Downgrade JP Morgan Overweight → Neutral
Nov-20-20 07:00AM  
Nov-13-20 07:59AM  
07:02AM  
07:00AM  
Nov-12-20 07:00AM  
Nov-07-20 08:01AM  
Nov-05-20 11:01PM  
09:25AM  
07:00AM  
Nov-02-20 04:15PM  
Oct-30-20 08:15AM  
Oct-29-20 12:35PM  
Oct-28-20 07:31AM  
07:00AM  
Oct-22-20 04:15PM  
07:00AM  
Oct-07-20 08:34AM  
Oct-05-20 04:15PM  
Sep-30-20 07:00AM  
Sep-28-20 03:09PM  
Sep-22-20 07:25AM  
Sep-08-20 07:00AM  
Sep-03-20 04:15PM  
07:00AM  
Aug-31-20 09:29AM  
07:00AM  
Aug-17-20 11:41AM  
Aug-13-20 01:48PM  
Aug-11-20 08:54AM  
Aug-06-20 09:55AM  
07:00AM  
Aug-04-20 07:00AM  
Aug-03-20 11:19AM  
07:00AM  
Jul-23-20 07:00AM  
Jul-18-20 07:16PM  
Jul-15-20 11:35AM  
Jul-07-20 02:43PM  
11:57AM  
11:30AM  
Jul-02-20 07:00AM  
Jun-18-20 08:53AM  
Jun-15-20 07:43AM  
Jun-10-20 02:00PM  
Jun-09-20 04:15PM  
Jun-08-20 03:40PM  
Jun-06-20 03:01AM  
03:00AM  
Jun-02-20 07:15AM  
Jun-01-20 04:01PM  
May-28-20 04:15PM  
May-27-20 11:35PM  
06:21PM  
04:01PM  
May-26-20 07:00AM  
12:36AM  
May-19-20 03:18PM  
May-18-20 02:47PM  
09:30AM  
09:21AM  
May-15-20 07:53AM  
07:00AM  
May-13-20 11:30AM  
May-11-20 02:45PM  
May-07-20 01:07PM  
07:00AM  
May-06-20 07:31PM  
08:55AM  
07:42AM  
07:00AM  
May-05-20 07:00AM  
May-04-20 04:15PM  
Apr-29-20 01:17PM  
01:06PM  
12:34PM  
Apr-27-20 05:50PM  
11:30AM  
Apr-26-20 07:51AM  
Apr-22-20 07:00AM  
06:16AM  
Apr-21-20 12:19PM  
Apr-20-20 09:06AM  
Apr-15-20 09:36AM  
Apr-14-20 06:29PM  
02:32PM  
Apr-13-20 12:27PM  
09:54AM  
Apr-10-20 02:06PM  
Apr-09-20 05:52PM  
04:45PM  
Apr-08-20 07:00AM  
Apr-03-20 06:04PM  
07:07AM  
07:00AM  
Apr-02-20 12:28PM  
07:00AM  
Apr-01-20 08:18AM  
Mar-30-20 07:00AM  
Mar-17-20 06:41AM  
Mar-16-20 07:10AM  
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Doyle AnthonyChief Financial OfficerAug 11Buy4.0854,000220,32054,000Aug 12 04:31 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.